Leukemia & Lymphoma最新文献_第9页

Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents. 现代复发/难治性外周t细胞淋巴瘤的预后：干细胞移植和新药物的影响

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-14 DOI: 10.1080/10428194.2025.2540437

Seda S Tolu, Caitlin Gribbin, Zhengming Chen, Madhav R Seshadri, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Hua-Jay J Cherng, Ahmed Sawas, Adrienne Phillips, Tsiporah Shore, Peter Martin, John P Leonard, Giorgio Inghirami, Koen van Besien, Barbara Pro, Jennifer E Amengual, Jia Ruan

{"title":"Outcomes of relapsed/refractory peripheral T-cell lymphoma in the modern era: impact of stem cell transplant and novel agents.","authors":"Seda S Tolu, Caitlin Gribbin, Zhengming Chen, Madhav R Seshadri, Evelyn Orlando, Justin Grenet, Rajbir Toor, Alexander Sanjurjo, Hua-Jay J Cherng, Ahmed Sawas, Adrienne Phillips, Tsiporah Shore, Peter Martin, John P Leonard, Giorgio Inghirami, Koen van Besien, Barbara Pro, Jennifer E Amengual, Jia Ruan","doi":"10.1080/10428194.2025.2540437","DOIUrl":"https://doi.org/10.1080/10428194.2025.2540437","url":null,"abstract":"Peripheral T-cell lymphoma (PTCL) is characterized by clinicopathologic heterogeneity with a frequently relapsing/refractory (R/R) course. The optimal sequencing and efficacy of novel agents and SCT in second-line and beyond remains yet to be determined. The objective of this dual-institution retrospective study is to assess outcomes in R/R nodal PTCL with respect to SCT and novel agents. A total of 148 patients were reviewed for baseline characteristics and treatment parameters. Endpoints were subsequent EFS (sEFS) and subsequent overall survival (sOS). The median sEFS and sOS for the entire cohort was 5.3 m (95% CI: 4.1 - 7.1) and 32.4 m (95% CI: 17.7 - 71.0), respectively. The median sEFS favored patients who received salvage SCT following either chemotherapy or novel agents (p = 0.005). The median sOS showed similar trend. Altogether, these data suggest that incorporation of novel agents in patients with and without SCT in second-line and beyond may improve outcomes compared to historical cohorts.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144855708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spontaneous remission of Epstein-Barr virus positive diffuse large B-cell lymphoma after relapse post axicabtagene ciloleucel chimeric antigen receptor T-cell therapy. 爱泼斯坦-巴尔病毒阳性弥漫性大b细胞淋巴瘤治疗后复发后自发性缓解。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-12 DOI: 10.1080/10428194.2025.2545928

Anthony Jeffrey, James Favaloro, Grace Wolyncewicz, Lisa Horgan, George Mason, Katrina Debosz, Michael Fulham, Arda Leyton, Andrew Colebatch, Edward Abadir

引用次数: 0

Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma. 罗米地辛和莫加单抗序贯治疗晚期皮肤t细胞淋巴瘤。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-11 DOI: 10.1080/10428194.2025.2542941

Emily R Gordon, Seda Tolu, Brigit A Lapolla, Megan H Trager, Oluwaseyi Adeuyan, Manuel A Pazos, Ted Piorczynski, David DeStephano, Susan E Bates, Barbara Pro, Jennifer E Amengual, Larisa J Geskin

{"title":"Romidepsin and mogamulizumab sequential treatment for advanced cutaneous T-cell lymphoma.","authors":"Emily R Gordon, Seda Tolu, Brigit A Lapolla, Megan H Trager, Oluwaseyi Adeuyan, Manuel A Pazos, Ted Piorczynski, David DeStephano, Susan E Bates, Barbara Pro, Jennifer E Amengual, Larisa J Geskin","doi":"10.1080/10428194.2025.2542941","DOIUrl":"https://doi.org/10.1080/10428194.2025.2542941","url":null,"abstract":"Management of advanced stage cutaneous T-cell lymphoma (CTCL) can be challenging due to lack of durable responses to currently available therapies and their side effects and toxicities. Romidepsin, a histone deacetylase inhibitor, and mogamulizumab, an anti-CCR4 monoclonal antibody, have demonstrated some efficacy as monotherapies, however, survival outcomes remain poor. This retrospective study evaluates the effectiveness of sequential romidepsin-mogamulizumab (Romi-Moga) therapy in 18 patients with advanced CTCL. The overall response rate was 67% in our cohort and time to next treatment was 15 months, which compared favorably to clinical trials of monotherapies. Patients who transitioned to mogamulizumab within one month of romidepsin discontinuation exhibited superior responses in skin, blood, and lymph nodes and longer time to next treatment. These findings suggest a potential beneficial effect of Romi-Moga therapy when administered in close sequence. Prospective studies are needed to validate these results and optimize treatment strategies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144821938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hematopoietic stem cell Transplants in the Philippines: barriers to accessibility. 菲律宾的造血干细胞移植：可及性障碍。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-09 DOI: 10.1080/10428194.2025.2544076

Adrian E Go, Erin Jay G Feliciano, Frances Dominique V Ho, Edward Christopher Dee

引用次数: 0

Severe hypertriglyceridemia associated with calaspargase pegol. 与天冬酰胺酶pegol相关的严重高甘油三酯血症。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-09 DOI: 10.1080/10428194.2025.2543578

Alexis K Kuhn, Madeleine O'Keefe, Mira Kohorst, Jessica Kalmes, Paul Galardy, Ashley Walter, John Guggenberger, Mostafa Salama, Siobhan Pittock, Catherine Martin

引用次数: 0

Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase. 以波纳替尼为基础的治疗在髓细胞期慢性髓性白血病患者的复发的结果和模式。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-09 DOI: 10.1080/10428194.2025.2542946

Omer Karrar, Hagop Kantarjian, Fadi G Haddad, Roberta S Azevedo, Ghayas Issa, Farhad Ravandi, Koji Sasaki, Jayastu Senapati, Hussein Abbas, Sara Dellasala, Elias Jabbour, Nicholas J Short

{"title":"Outcomes and patterns of relapse with ponatinib-based therapy in patients with chronic myeloid leukemia in myeloid blast phase.","authors":"Omer Karrar, Hagop Kantarjian, Fadi G Haddad, Roberta S Azevedo, Ghayas Issa, Farhad Ravandi, Koji Sasaki, Jayastu Senapati, Hussein Abbas, Sara Dellasala, Elias Jabbour, Nicholas J Short","doi":"10.1080/10428194.2025.2542946","DOIUrl":"https://doi.org/10.1080/10428194.2025.2542946","url":null,"abstract":"We analyzed 76 patients who received a ponatinib-based regimen, either as monotherapy or in combination with chemotherapy, for chronic myeloid leukemia in myeloid blast phase (CML-MBP). The rate of morphological remission with or without count recovery (i.e. overall response rate [ORR]) was 49%. Patients who received a ponatinib-based regimen as their first therapy for CML-MBP had better ORR than those received ponatinib as salvage (60% versus 27%, respectively; p = 0.006). ORR was also higher with ponatinib combination therapy than monotherapy (54% versus 29%, respectively; p = 0.06). For the entire cohort, the median RFS and OS were 11.9 and 8.5 months, respectively. Responding patients who underwent allogeneic HSCT had superior outcomes to those who did not (2-year OS 79% versus 38%, respectively; p = 0.05). After ponatinib failure, outcomes were dismal (median OS: 3.9 months). Ponatinib-based regimens are effective in CML-MBP, especially when used as first therapy and in combination with chemotherapy, followed by HSCT.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-8"},"PeriodicalIF":2.2,"publicationDate":"2025-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144812204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Intrathecal methotrexate for meningeal acute lymphoblastic leukemia in a hemodialysis patient. 鞘内甲氨蝶呤治疗血液透析患者脑膜急性淋巴细胞白血病1例。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-09 DOI: 10.1080/10428194.2025.2544067

Shogo Matsui, Wataru Nakahara, Shungo Fukuda, Mako Hosoya, Kodai Ueshima, Yuka Umeki, Yuta Nakagawa, Naoki Adachi, Yuya Hayasaka, Nayu Matsuoka, Shoma Yoshida, Riko Saito, Hitomi Matsunaga, Noritoshi Kato, Naohiko Fujii, Shuji Ueda

引用次数: 0

The evolution of treatment for pediatric advanced stage classic Hodgkin lymphoma - a narrative literature review. 儿童晚期经典霍奇金淋巴瘤治疗的演变-叙述性文献综述。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-08 DOI: 10.1080/10428194.2025.2531154

Nisha Shariff, Foo Jen Chun, Susan K Parsons, David C Hodgson

引用次数: 0

Clinical characteristics and prognosis of primary central nervous system lymphoma in China: a single-center retrospective analysis of 325 patients. 中国原发性中枢神经系统淋巴瘤的临床特点和预后：325例患者的单中心回顾性分析

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-08 DOI: 10.1080/10428194.2025.2541016

Xiang Zhou, Yunan Ling, Jingjing Ma, Zhiguang Lin, Yan Ma, Bobin Chen

{"title":"Clinical characteristics and prognosis of primary central nervous system lymphoma in China: a single-center retrospective analysis of 325 patients.","authors":"Xiang Zhou, Yunan Ling, Jingjing Ma, Zhiguang Lin, Yan Ma, Bobin Chen","doi":"10.1080/10428194.2025.2541016","DOIUrl":"https://doi.org/10.1080/10428194.2025.2541016","url":null,"abstract":"Large-scale studies characterizing the clinicopathological features of primary central nervous system lymphoma (PCNSL) in China remain limited. This study analyzed 325 PCNSL cases between January 2016 and June 2022, aiming to characterize the features and identify prognostic factors for overall survival (OS) and progression-free survival (PFS) in this population. This cohort demonstrated male predominance with median age of 58 years. Neuroimaging and cerebrospinal fluid evaluation revealed prevalence of multifocal intracranial involvement and leptomeningeal infiltration. With a median follow-up of 29.5 months (range 2.6-137.7), the median OS and PFS for the entire cohort were 63.1 months (95%CI, 52.1-74.1) and 14.7 months (95%CI, 11.1-18.3), respectively. Multivariable analysis identified three independent predictors of inferior overall survival: age ≥ 60, pre-biopsy corticosteroid, and lymphocyte count < 0.875 × 109/L. ECOG PS ≥ 2 and Bcl-2 positivity predicted reduced PFS. This study highlights characteristics of Chinese PCNSL patients, providing population-specific data to optimize risk stratification and therapies.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144799523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia. 急性髓系白血病同种异体造血细胞移植后预防性鞘内化疗的疗效及中枢神经系统复发的危险因素。

IF 2.2 4区医学

Leukemia & Lymphoma Pub Date : 2025-08-07 DOI: 10.1080/10428194.2025.2541302

Hyunkyung Park, Je-Hwan Lee, Jung-Hee Lee, Han-Seung Park, Eun-Ji Choi, Kyoo-Hyung Lee, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Yunsuk Choi

{"title":"Effectiveness of prophylactic intrathecal chemotherapy and risk factors of central nervous system relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.","authors":"Hyunkyung Park, Je-Hwan Lee, Jung-Hee Lee, Han-Seung Park, Eun-Ji Choi, Kyoo-Hyung Lee, Young-Shin Lee, Young-Ah Kang, Mijin Jeon, Ji Min Woo, Hyeran Kang, Yunsuk Choi","doi":"10.1080/10428194.2025.2541302","DOIUrl":"https://doi.org/10.1080/10428194.2025.2541302","url":null,"abstract":"Central nervous system (CNS) relapse in acute myeloid leukemia (AML) is uncommon but associated with poor outcomes. This retrospective study analyzed 960 AML patients who underwent hematopoietic cell transplantation (HCT) at Asan Medical Center between 2000 and 2020 to assess the efficacy of prophylactic intrathecal chemotherapy. Per protocol, patients received up to four intrathecal methotrexate (MTX). CNS relapse occurred in 2.8%, with a median onset of 6.3 months post-HCT. The 5-year CNS relapse rate was lower in the prophylactic MTX group compared to the non-MTX group (2.7% vs. 7.4%, p = 0.132), though not statistically significant. Increased number of intrathecal treatments did not reduce CNS relapse. Risk factors for CNS relapse included high white blood cell count, extramedullary disease, FAB M3/M4, and poor-risk cytogenetics. Prior CNS involvement was significant only in univariate analysis. These findings suggest intrathecal prophylaxis may benefit high-risk patients but is not necessary for all AML patients undergoing HCT.","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.2,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144794868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0